News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Sanofi-Aventis (France) Hopes to Win Genzyme Corporation for $76/Share; Said to be Ceiling Price
January 14, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
(Reuters) - French drugmaker Sanofi-Aventis hopes to reach a takeover deal that would value U.S. target Genzyme (NasdaqGS:GENZ - News) at around $76 per share, or some $20 billion, the French daily newspaper Le Figaro said on Friday.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Europe
Sanofi (France)
MORE ON THIS TOPIC
Podcast
Lilly’s Obesity Pill Heads to the FDA, AbbVie Bets on Psychedelics, HHS Unveils More Change
August 27, 2025
·
1 min read
·
Jef Akst
Acquisitions
Unswayed by Cerevel Failure, AbbVie Buys Gilgamesh’s Depression Drug for $1.2B
August 25, 2025
·
3 min read
·
Annalee Armstrong
IN PARTNERSHIP WITH CRESSET
Why AI Won’t Save the 90% of Clinical Trials That Still Fail
August 21, 2025
·
1 min read
·
Lori Ellis
GLP-1
Novo Teams Up With GoodRx for Lower-Price GLP-1s, Giving DTC Another Shot
August 18, 2025
·
1 min read
·
Annalee Armstrong